A live webcast of the presentation can be accessed by visiting the investor relations section of the Genocea website at www.ir.genocea.com. A replay of the webcast will be archived for 30 days following the presentation.
Genocea is harnessing the power of T cell immunity to develop the next generation of vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but are difficult to target using traditional discovery methods. Genocea is able to identify protective T cell antigens in humans exposed to a pathogen using ATLAS™, its proprietary technology platform, potentially enabling vaccines against pathogens for which vaccine solutions do not exist or are sub-optimal. Genocea's pipeline of novel clinical stage T cell enabled vaccines includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis and malaria. For more information, please visit the company's website at www.genocea.com.
News Provided by Acquire Media